ArticleInsights into imaging2026
Prospective validation of an AI software for detecting clinically significant prostate cancer on biparametric MRI.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence in prostate biopsy: diagnostic applications, risk stratification, and precision oncology.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesTo evaluate the feasibility and safety (primary endpoints), and performance (secondary endpoint) of a new artificial intelligence (AI) software for detecting clinically significant prostate cancer (csPCa) on biparametric MRI (bpMRI) compared to an expert radiologist. MATERIALS AND
methodsIn this prospective study at St. Olavs Hospital, Norway (December 2023-October 2024), 89 consecutive biopsy-naïve men underwent bpMRI for suspected PCa. Scans were interpreted by a radiologist using PI-RADS v2.1 and a radiomics-based AI software. Biopsies were obtained from all radiologist- and/or AI-identified lesions. csPCa was defined as ISUP ≥ 2. Feasibility was defined by a < 10% software-failure rate, and safety by the absence of serious adverse device effects (SADEs). Performance was evaluated with ROC, free-response ROC, and precision-recall curves.
resultsAmong 89 patients eligible for primary endpoints evaluation, the software demonstrated feasibility (7% failure rate) and safety (no SADEs). Among 76 eligible for secondary endpoint evaluation (median age 68 years [IQR: 63-73]), csPCa was found in 51% (39/76). Patient-level, software achieved an area under the ROC curve [95% CI] of 0.90 [0.83, 0.96] versus 0.86 [0.76, 0.93] (p = 0.25). At a retrospectively optimized threshold matching the radiologist's patient-level sensitivity at PI-RADS 3 (0.92), software achieved specificity of 0.68 [0.57, 0.78] versus 0.57 [0.46, 0.68] (p = 0.29). Lesion-level, software achieved higher average precision (0.61 [0.52, 0.71] vs. 0.56 [0.46, 0.67]) and lower average false-positive per patient (0.33 [0.22, 0.43] vs. 0.41 [0.30, 0.52]) at the optimized threshold.
conclusionThe software was feasible and safe, and diagnostic performance showed potential to reduce unnecessary biopsies. CRITICAL RELEVANCE STATEMENT: This clinically validated artificial intelligence software enables feasible and safe detection of clinically significant prostate cancer on biparametric MRI, with demonstrated potential to reduce unnecessary biopsies and improve diagnostic accuracy, indicating potential for integration into clinical prostate cancer care. KEY POINTS: A fully automated radiomics software for clinically significant prostate cancer detection on biparametric MRI was prospectively clinically validated. The software demonstrated feasibility and safety, with potential to reduce unnecessary biopsies and improve diagnostic accuracy. The investigated radiomics software has the potential for integration into clinical prostate cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.